Abstract: There are no reliable clinical bio-markers of survival prognosis, patient's risk stratification and treatment prediction for epithelial ovarian cancers(EOC). The most common type of the human EOC is a high grade serous EOC. This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an method for a prognosis of survival of a subject diagnosed with EOC, the method comprising determining in a sample of the subject gene expression level of at least one gene in the list of Evi1 pathway genes; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression threshold value will define the risk group of the subject and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy.

Abstract: The present invention relates to a method of identification of clinically and genetically distinct sub-groups of patients subject to a medical condition, particularly breast, lung, and colon cancer patients using a composition of respective gene expression values for certain gene pairs. Sense-antisense gene pairs (SAGPs) which are relevant for a medical condition and the disease prognosis are used by the method to generate statistical models based on the expression values of the SAGPs. SAGPs for which the statistical models are found to have high value in prognosis of the variation of medical condition and the diseases are selected and integrated in the prognostic signature including specified parameters (e.g. cut-off values) of the prognostic model.

Abstract: A method for the prognosis of overall survival or prediction of therapeutic outcome for a patient suffering from epithelial ovarian cancer (EOC), comprising: a. providing a metabolism response sample from the patient, b. determining the expression level of microRNA family lethal-7b (let-7b) in the sample; c. using the expression level of the let-7b to obtain the prognosis of overall survival or prediction of therapeutic outcome for the patient.